These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 30952563)

  • 1. Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component.
    Moretto R; Morano F; Ongaro E; Rossini D; Pietrantonio F; Casagrande M; Antoniotti C; Corallo S; Marmorino F; Cortiula F; Nichetti F; Borelli B; Zucchelli G; Boccaccino A; Masi G; de Braud F; Falcone A; Cremolini C
    Clin Colorectal Cancer; 2019 Jun; 18(2):116-124. PubMed ID: 30952563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer.
    Moretto R; Cremolini C; Rossini D; Pietrantonio F; Battaglin F; Mennitto A; Bergamo F; Loupakis F; Marmorino F; Berenato R; Marsico VA; Caporale M; Antoniotti C; Masi G; Salvatore L; Borelli B; Fontanini G; Lonardi S; De Braud F; Falcone A
    Oncologist; 2016 Aug; 21(8):988-94. PubMed ID: 27382031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).
    Huemer F; Thaler J; Piringer G; Hackl H; Pleyer L; Hufnagl C; Weiss L; Greil R
    BMC Cancer; 2018 Jan; 18(1):11. PubMed ID: 29298682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Final Analysis of Outcomes and RAS/BRAF Status in a Randomized Phase 3 Study of Panitumumab and Best Supportive Care in Chemorefractory Wild Type KRAS Metastatic Colorectal Cancer.
    Kim TW; Elme A; Park JO; Udrea AA; Kim SY; Ahn JB; Valencia RV; Krishnan S; Manojlovic N; Guan X; Lofton-Day C; Jung AS; Vrdoljak E
    Clin Colorectal Cancer; 2018 Sep; 17(3):206-214. PubMed ID: 29703606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic and Predictive Value of HER2 Amplification in Patients With Metastatic Colorectal Cancer.
    Sawada K; Nakamura Y; Yamanaka T; Kuboki Y; Yamaguchi D; Yuki S; Yoshino T; Komatsu Y; Sakamoto N; Okamoto W; Fujii S
    Clin Colorectal Cancer; 2018 Sep; 17(3):198-205. PubMed ID: 29866615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding the Prognostic Value of Primary Tumor Location and KRAS in Metastatic Colorectal Cancer: A Post Hoc Analysis of the OPTIMOX3 DREAM Phase III Study.
    Chibaudel B; André T; Tournigand C; Louvet C; Benetkiewicz M; Larsen AK; de Gramont A
    Clin Colorectal Cancer; 2020 Sep; 19(3):200-208.e1. PubMed ID: 32303437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mucinous Histology Is Associated with Resistance to Anti-EGFR Therapy in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer.
    Wang C; Sandhu J; Fakih M
    Oncologist; 2022 Mar; 27(2):104-109. PubMed ID: 35641204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy.
    Llovet P; Sastre J; Ortega JS; Bando I; Ferrer M; García-Alfonso P; Donnay O; Carrato A; Jiménez A; Aranda E; León A; Grávalos C; Cámara JC; Feliú J; Sanchíz B; Caldés T; Díaz-Rubio E
    Mol Diagn Ther; 2015 Dec; 19(6):397-408. PubMed ID: 26341080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of K-RAS and B-RAF mutations as biomarkers in metastatic colorectal cancer.
    Selcukbiricik F; Erdamar S; Ozkurt CU; Molinas Mandel N; Demirelli F; Ozguroglu M; Tural D; Buyukunal E; Serdengecti S
    J BUON; 2013; 18(1):116-23. PubMed ID: 23613396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colorectal carcinomas with mucinous differentiation are associated with high frequent mutation of KRAS or BRAF mutations, irrespective of quantity of mucinous component.
    Li X; Sun K; Liao X; Gao H; Zhu H; Xu R
    BMC Cancer; 2020 May; 20(1):400. PubMed ID: 32384877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status.
    Siena S; Rivera F; Taieb J; Peeters M; Prenen H; Koukakis R; Demonty G; Köhne CH
    Clin Colorectal Cancer; 2018 Mar; 17(1):50-57.e8. PubMed ID: 29096990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy.
    Vidal J; Bellosillo B; Santos Vivas C; García-Alfonso P; Carrato A; Cano MT; García-Carbonero R; Élez E; Losa F; Massutí B; Valladares-Ayerbes M; Viéitez JM; Manzano JL; Azuara D; Gallego J; Pairet S; Capellá G; Salazar R; Tabernero J; Aranda E; Montagut C
    Ann Oncol; 2019 Mar; 30(3):439-446. PubMed ID: 30689692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.
    Schirripa M; Cremolini C; Loupakis F; Morvillo M; Bergamo F; Zoratto F; Salvatore L; Antoniotti C; Marmorino F; Sensi E; Lupi C; Fontanini G; De Gregorio V; Giannini R; Basolo F; Masi G; Falcone A
    Int J Cancer; 2015 Jan; 136(1):83-90. PubMed ID: 24806288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic importance of tumor location and anti-EGFR therapy in patients with K-RAS wild type metastatic colorectal cancer.
    Kucukoner M; Oztekin E; Akdeniz N; Morkuzu S; Yerlikaya H; Urakci Z; Kaplan MA; Isikdogan A
    J BUON; 2019; 24(4):1501-1506. PubMed ID: 31646798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Right or Left Primary Site of Colorectal Cancer: Outcomes From the Molecular Analysis of the AGITG MAX Trial.
    Tapia Rico G; Price T; Tebbutt N; Hardingham J; Lee C; Buizen L; Wilson K; Gebski V; Townsend A
    Clin Colorectal Cancer; 2019 Jun; 18(2):141-148. PubMed ID: 30713134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.
    Ålgars A; Sundström J; Lintunen M; Jokilehto T; Kytölä S; Kaare M; Vainionpää R; Orpana A; Österlund P; Ristimäki A; Carpen O; Ristamäki R
    Int J Cancer; 2017 Feb; 140(4):922-929. PubMed ID: 27879995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metastatic Bulk Independently Predicts Outcomes for EGFR Precision Targeting in Colorectal Cancer.
    Kratz JD; Uboha NV; Lubner SJ; Mulkerin DL; Clipson L; Yi Y; Yu M; Matkowskyj KA; LoConte NK; Deming DA
    J Natl Compr Canc Netw; 2018 Dec; 16(12):1442-1450. PubMed ID: 30545991
    [No Abstract]   [Full Text] [Related]  

  • 18. Integrating
    Ntavatzikos A; Spathis A; Patapis P; Machairas N; Peros G; Konstantoudakis S; Leventakou D; Panayiotides IG; Karakitsos P; Koumarianou A
    World J Gastroenterol; 2017 Aug; 23(32):5913-5924. PubMed ID: 28932083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Impact of PI3K/BRAF Mutations in RAS Wild Metastatic Colorectal Cancer: Meta-analysis Results.
    Mohamed A; Twardy B; AbdAllah N; Akhras A; Ismail H; Zordok M; Schrapp K; Attumi T; Tesfaye A; El-Rayes B
    J Gastrointest Cancer; 2019 Jun; 50(2):269-275. PubMed ID: 29388061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging RAS, BRAF, and EGFR mutations in cell-free DNA of metastatic colorectal patients are associated with both primary and secondary resistance to first-line anti-EGFR therapy.
    Yamada T; Matsuda A; Takahashi G; Iwai T; Takeda K; Ueda K; Kuriyama S; Koizumi M; Shinji S; Yokoyama Y; Ohta R; Yoshida H
    Int J Clin Oncol; 2020 Aug; 25(8):1523-1532. PubMed ID: 32394048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.